Abstract
Unlabelled
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight is a significant risk factor. The aim was to build an algorithm along with a scoring system for histopathologic classification of liver lesions that covers the entire spectrum of lesions in morbidly obese patients. A cohort of 679 obese patients undergoing liver biopsy at the time of bariatric surgery was studied. An algorithm for segregating lesions into normal liver, NAFLD, or nonalcoholic steatohepatitis (NASH) was built based on semiquantitative evaluation of steatosis, hepatocellular ballooning, and lobular inflammation. For each case, the SAF score was created including the semiquantitative scoring of steatosis (S), activity (A), and fibrosis (F). Based on the algorithm, 230 obese patients (34%) were categorized as NASH, 291 (43%) as NAFLD without NASH, and 158 (23%) as not NAFLD. The activity score (ballooning + lobular inflammation) enabled discriminating NASH because all patients with NASH had A ≥ 2, whereas no patients with A < 2 had NASH. This score was closely correlated with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (P < 0.0001, analysis of variance [ANOVA]). Comparison of transaminase levels between patients with normal liver and pure steatosis did not reveal significant differences, thus lending support to the proposal not to include steatosis in the activity score but to report it separately in the SAF score. In the validation series, the interobserver agreement for the diagnosis of NASH was excellent (κ = 0.80) between liver pathologists. There was no discrepancy between the initial diagnosis and the diagnosis proposed using the algorithm.Conclusion
We propose a simple but robust algorithm for categorizing liver lesions in NAFLD patients. Because liver lesions in obese patients may display a continuous spectrum of histologic lesions, we suggest describing liver lesions using the SAF score.Full text links
Read article at publisher's site: https://doi.org/10.1002/hep.25889
Read article for free, from open access legal sources, via Unpaywall: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.25889
References
Articles referenced by this article (30)
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.
J Hepatol, (1):234-240 2011
MED: 21703178
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.
Hepatology, (6):1387-1395 2004
MED: 15565570
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
Diabetes, (8):1844-1850 2001
MED: 11473047
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.
Hepatology, (2):367-372 2002
MED: 11826410
Trends in body weight and overweight in the U.S. population.
Nutr Rev, (4 Pt 2):S97-100 1996
MED: 8700458
Hepatic histology in obese patients undergoing bariatric surgery.
J Hepatol, (4):600-606 2006
MED: 16899321
Endpoints and clinical trial design for nonalcoholic steatohepatitis.
Hepatology, (1):344-353 2011
MED: 21520200
Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
Hepatology, (6):1313-1321 2005
MED: 15915461
Show 10 more references (10 of 30)
Citations & impact
Impact metrics
Article citations
Machine Learning Models for Predicting Significant Liver Fibrosis in Patients with Severe Obesity and Nonalcoholic Fatty Liver Disease.
Obes Surg, 25 Oct 2024
Cited by: 0 articles | PMID: 39448457
Liver biopsy-proven non-alcoholic fatty liver disease predicts no impact on antiviral response in patients with chronic hepatitis B.
Clinics (Sao Paulo), 79:100493, 26 Sep 2024
Cited by: 0 articles | PMID: 39332149 | PMCID: PMC11467630
Strategy for treating MAFLD: Electroacupuncture alleviates hepatic steatosis and fibrosis by enhancing AMPK mediated glycolipid metabolism and autophagy in T2DM rats.
Diabetol Metab Syndr, 16(1):218, 11 Sep 2024
Cited by: 0 articles | PMID: 39261952 | PMCID: PMC11389443
DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease.
Clin Mol Hepatol, 30(4):824-844, 25 Jul 2024
Cited by: 0 articles | PMID: 39048522 | PMCID: PMC11540403
Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective study.
Sci Rep, 14(1):17558, 30 Jul 2024
Cited by: 0 articles | PMID: 39080285 | PMCID: PMC11289378
Go to all (402) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
Obes Surg, 15(3):310-315, 01 Mar 2005
Cited by: 169 articles | PMID: 15826462
Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
Obes Surg, 16(12):1584-1593, 01 Dec 2006
Cited by: 34 articles | PMID: 17217634
Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.
Chirurgia (Bucur), 107(6):772-779, 01 Nov 2012
Cited by: 16 articles | PMID: 23294957
Non-alcoholic steatohepatitis in children.
Pediatr Transplant, 8(6):613-618, 01 Dec 2004
Cited by: 38 articles | PMID: 15598336
Review